Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

NCT02836899 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2026-03-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether nitric oxide is effective in the treatment of acute kidney injury in cardiac surgical patients with sign and laboratory data suggesting endothelial dysfunction undergoing prolonged cardiopulmonary bypass.

Conditions

Interventions

DRUG

Nitric Oxide

Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.

OTHER

Placebo

This is the placebo group. Nitrogen will be added instead of nitric oxide.

Sponsors & Collaborators

  • Ichinose, Fumito, M.D., Ph.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • Kenneth, Shelton, M.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • Kacmarek, Robert M., Ph.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • Sundt, Thoralf M., M.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • Villavicencio-Theoduloz, Mauricio A., M.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • Thompson, Boyd Taylor, M.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • Bonventre, Joseph V., M.D., Brigham Women Hospital

    collaborator UNKNOWN
  • Shann, Kenneth G., Massachusetts General Hospital

    collaborator UNKNOWN
  • Zapol, Warren M., M.D.

    collaborator INDIV
  • Marrazzo, Francesco, M.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • Spina, Stefano, M.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • Zadek, Francesco, M.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • Rezoagli, Emanuele, M.D., Massachusetts General Hospital

    collaborator UNKNOWN
  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH
  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Lorenzo Berra, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-08
Primary Completion
2025-08-15
Completion
2025-08-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02836899 on ClinicalTrials.gov